HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bernd Groner Selected Research

Peptide Aptamers

2/2008Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition.
12/2006Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
6/2005Peptide aptamers: recent developments for cancer therapy.
3/2004The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells.
12/2003Bifunctional recombinant proteins in cancer therapy: cell penetrating peptide aptamers as inhibitors of growth factor signaling.
9/2003Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Bernd Groner Research Topics

Disease

40Neoplasms (Cancer)
01/2017 - 07/2003
8Breast Neoplasms (Breast Cancer)
01/2014 - 12/2006
4Neoplasm Metastasis (Metastasis)
01/2018 - 04/2009
4Glioblastoma (Glioblastoma Multiforme)
11/2015 - 02/2008
3Inflammation (Inflammations)
01/2017 - 01/2010
3Carcinogenesis
11/2007 - 11/2004
2Glioma (Gliomas)
12/2013 - 07/2013
2Adenocarcinoma
01/2012 - 05/2010
1Renal Cell Carcinoma (Grawitz Tumor)
01/2018
1Hepatocellular Carcinoma (Hepatoma)
08/2015
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
03/2015
1Hematologic Neoplasms (Hematological Malignancy)
03/2015
1Shock
12/2014
1Fever (Fevers)
12/2014
1Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome)
12/2014
1Mesothelioma
10/2014
1Squamous Cell Carcinoma of Head and Neck
12/2013
1Nervous System Diseases (Neurological Disorders)
06/2012
1Alzheimer Disease (Alzheimer's Disease)
06/2012
1Psoriasis (Pustulosis Palmaris et Plantaris)
06/2012
1Colorectal Neoplasms (Colorectal Cancer)
06/2012
1Infections
05/2010
1Leukemia
12/2005
1Carcinoma (Carcinomatosis)
11/2004

Drug/Important Bio-Agent (IBA)

13Peptides (Polypeptides)IBA
08/2015 - 12/2003
11Pharmaceutical PreparationsIBA
01/2017 - 08/2004
11Proteins (Proteins, Gene)FDA Link
11/2015 - 12/2003
6Transcription Factors (Transcription Factor)IBA
01/2017 - 03/2004
6STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
01/2014 - 03/2004
6Peptide AptamersIBA
02/2008 - 09/2003
5Phosphotransferases (Kinase)IBA
03/2015 - 09/2003
5Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
08/2013 - 12/2003
5DNA (Deoxyribonucleic Acid)IBA
08/2013 - 03/2004
3CytokinesIBA
01/2017 - 06/2012
3Small Interfering RNA (siRNA)IBA
10/2014 - 07/2012
3LigandsIBA
08/2013 - 01/2010
3ErbB Receptors (EGF Receptor)IBA
12/2006 - 09/2003
2Histone Deacetylases (Histone Deacetylase)IBA
01/2018 - 07/2003
2Biological ProductsIBA
01/2017 - 03/2010
2MicroRNAs (MicroRNA)IBA
11/2015 - 01/2014
2SurvivinIBA
02/2014 - 07/2012
2Interleukin-6 (Interleukin 6)IBA
01/2014 - 01/2010
2STAT5 Transcription FactorIBA
08/2013 - 12/2005
2Recombinant ProteinsIBA
08/2013 - 12/2003
2Estrogens (Estrogen)FDA Link
01/2012 - 05/2010
2Phenobarbital (Luminal)FDA Link
01/2012 - 05/2010
2Progesterone Receptors (Progesterone Receptor)IBA
01/2012 - 05/2010
2Cyclin D1IBA
11/2007 - 11/2004
1Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
01/2018
1Cell Adhesion MoleculesIBA
01/2018
1Cadherins (E-Cadherin)IBA
01/2018
1ChromatinIBA
11/2015
1Gadolinium DTPA (Magnevist)FDA Link
08/2015
1Doxorubicin (Adriamycin)FDA LinkGeneric
08/2015
1Sorafenib (BAY 43-9006)FDA Link
08/2015
1IntegrinsIBA
08/2015
1EndotoxinsIBA
12/2014
1CurcuminIBA
10/2014
1Neoplasm Antigens (Tumor Antigens)IBA
01/2014
1VaccinesIBA
01/2014
1Therapeutic UsesIBA
12/2013
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
12/2013
1ThioredoxinsIBA
07/2012
1Recombinant Fusion ProteinsIBA
07/2012
1ApoferritinsIBA
07/2012
1Topoisomerase I InhibitorsIBA
06/2012
1ChemokinesIBA
06/2012
1Cytotoxins (Cytolysins)IBA
06/2012
1Irinotecan (Camptosar)FDA LinkGeneric
06/2012
1Transforming Growth Factors (Transforming Growth Factor)IBA
06/2012
1Aromatase InhibitorsIBA
01/2012
1CollagenIBA
12/2010
1ProlactinIBA
01/2008
1tanespimycin (17AAG)IBA
01/2008
1Paclitaxel (Taxol)FDA LinkGeneric
12/2006
1Insulin-Like Growth Factor I (IGF-1)IBA
12/2006
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
12/2006
1Neuregulin-1 (Neuregulin 1)IBA
12/2006
1Tyrosine Kinase InhibitorsIBA
12/2005
1Tyrosine (L-Tyrosine)FDA Link
12/2005
1IGF Type 1 Receptor (IGF 1 Receptor)IBA
03/2005
1Peptide Initiation Factors (Initiation Factor)IBA
11/2004
1Eukaryotic Initiation Factor-4EIBA
11/2004
1Estrogen Receptor alphaIBA
11/2004
1Lactoglobulins (beta-Lactoglobulin)FDA Link
11/2004
1Estrogen ReceptorsIBA
11/2004
1Monoclonal AntibodiesIBA
08/2004
1Insulin-Like PeptidesIBA
08/2004
1Insulin (Novolin)FDA Link
08/2004
1Immunotoxins (Immunotoxin)IBA
12/2003
1Indicators and Reagents (Reagents)IBA
12/2003
1tyrosine receptor (receptor, tyrosine)IBA
09/2003
1Epidermal Growth Factor (EGF)IBA
09/2003

Therapy/Procedure

19Therapeutics
01/2018 - 07/2003
4Transplantation
01/2014 - 05/2010
3Drug Therapy (Chemotherapy)
08/2015 - 12/2006
2Immunotherapy
01/2014 - 04/2009
1Duration of Therapy
12/2013
1Cell- and Tissue-Based Therapy (Cell Therapy)
12/2003